Venetoclax: all 546 studies that test it
Page 1 of 6. Open to participants first (240), then studies with results posted, then the rest; newest registration first within each.
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingNCT07862517Phase 2
- Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingNCT07847957Phase 1/2
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
- Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AMLNot yet recruitingNCT07828535Phase 1
- Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingNCT07814339Phase 1
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT07754799Phase 2
- A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT07743112Phase 2
- Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingNCT07738887Phase 2
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT07734038Phase 2
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNot yet recruitingNCT07722767Phase 1
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingNCT07719556Phase 2
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsRecruitingNCT07713732Phase 1
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPNRecruitingNCT07710534Phase 2
- Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingNCT07679334Phase 1
- VA Consolidation in Intermediate-Risk AMLRecruitingNCT07672262Phase 2
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingNCT07643103Phase 2
- VA Induction and Bridging Transplantation for Hypoplastic/Secondary AMLNot yet recruitingNCT07635485Not applicable
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLNot yet recruitingNCT07605949Phase 2
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT07557056Phase 2
- Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLNot yet recruitingNCT07539818Phase 3
- A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALLNot yet recruitingNCT07522801Phase 2
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaRecruitingNCT07514936Phase 3
- VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm TrialRecruitingNCT07514832Phase 2
- Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
- Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic LeukemiaRecruitingNCT07512700Phase 2
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingNCT07511062Phase 1
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNCT07493161Not applicable
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLRecruitingNCT07490288Not applicable
- Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid LeukemiaNot yet recruitingNCT07486726Phase 1/2
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingNCT07486479Phase 3
- Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)RecruitingNCT07481175Phase 1
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaRecruitingNCT07439211Phase 1
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)RecruitingNCT07437950Phase 2
- FLT3-ITD Targeted Therapy in Fit AML PatientsNot yet recruitingNCT07425808Phase 2/3
- Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus VenetoclaxNot yet recruitingNCT07407660Phase 3
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingNCT07407140Phase 3
- A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaRecruitingNCT07392242Phase 2
- Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney TransplantationRecruitingNCT07358195Early Phase 1
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingNCT07311746Phase 1/2
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaRecruitingNCT07283094Phase 1
- Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyNot yet recruitingNCT07264010Phase 2/3
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingNCT07255872Phase 2/3
- Maintenance Venetoclax in AML Fit PatientsRecruitingNCT07244367Not applicable
- Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSRecruitingNCT07238686Phase 2
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingNCT07228273Phase 2
- Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialRecruitingNCT07218510Phase 2
- Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)RecruitingNCT07183878Not applicable
- HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingNCT07175415Phase 1/2
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
- Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)Not yet recruitingNCT07153497Phase 2
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxRecruitingNCT07148180Phase 1/2
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07133997Phase 1
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive InductionNot yet recruitingNCT07082452Phase 3
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingNCT07060001Phase 2
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingNCT07059975Early Phase 1
- VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTNot yet recruitingNCT07052422Phase 2/3
- Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic SyndromesRecruitingNCT07047183Phase 2
- Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaRecruitingNCT07044687Phase 4
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid MalignanciesRecruitingNCT07044544Phase 1
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
- Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseRecruitingNCT07023588Phase 2
- Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingNCT07014917Phase 2
- Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsRecruitingNCT07012447Phase 2
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingNCT07007312Phase 3
- Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm PatientsRecruitingNCT07007052Phase 2
- Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous LineageNot yet recruitingNCT06991920Not applicable
- Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingNCT06954987Phase 2
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsRecruitingNCT06928376Phase 2
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingNCT06917911Phase 2
- Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Phase 2/3
- Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid LeukemiaNot yet recruitingNCT06841952Not applicable
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT06810778Phase 1/2
- Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
- Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyRecruitingNCT06782542Phase 2
- A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)RecruitingNCT06773208Phase 2
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Phase 2/3
- CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLNot yet recruitingNCT06763666Phase 4
- Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLRecruitingNCT06757855Phase 1/2
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Phase 2
- VHAG in Treating R/R T-ALL/LBLRecruitingNCT06742463Phase 2
- Venetoclax and Decitabine in R/R T-ALLRecruitingNCT06712121Phase 2
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
- Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionRecruitingNCT06686108Phase 2
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
- Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyRecruitingNCT06643962Not applicable
- Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLRecruitingNCT06635681Phase 2
- APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLRecruitingNCT06634394Phase 1
- Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLRecruitingNCT06621212Phase 2
- Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AMLRecruitingNCT06621199Phase 2
- Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLRecruitingNCT06611839Phase 1/2
- Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALLRecruitingNCT06578546Phase 2
- RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRRecruitingNCT06571825Phase 4
- The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationRecruitingNCT06561880Phase 1/2
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingNCT06561074Phase 2